Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors

Gracell Biotechnologies, Inc. announced an exclusive license agreement with FutureGen Biopharm to develop engineered immune cell therapies targeting Claudin 18.2, a tumor-specific marker that is overexpressed in a variety of tumor tissues, including in gastric or gastroesophageal junction cancers.